ATLANTA, Oct. 28, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Friday, November 7, 2014 at 9:00 a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.
To access the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international). A live audio webcast of the call and the archived webcast will be available in the Investors section of the Biota website at http://www.biotapharma.com.
Biota is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates: (i) laninamivir octanoate, which is being developed for the treatment of influenza A and B infections; and (ii) vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses in development for the treatment of human rhinovirus-infected patients with underlying respiratory illnesses, such as moderate to severe asthma and chronic obstructive pulmonary disease (COPD). The Company is also conducting IND-enabling studies with BTA-C585, an orally bioavailable F-protein inhibitor, in development for the treatment of respiratory syncytial virus infections. For additional information about the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Holdings Limited.
CONTACT: Joseph M. Patti President & CEO (678) 221-3352 firstname.lastname@example.org
Source:Biota Pharmaceuticals, Inc